A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas

Oncology

Volumn 78, Issue 2, 2010, Pages 125-129

  Lo, Shelly S ^a,g   Khorana, Alok A ^b   Javle, Milind ^c   Simon, Sheryl ^d   Kiefer, Gauri ^d   Rajasenan, Kiran ^d   Wang, Hong ^d   Hantel, Alexander ^e   Shayne, Michelle ^b   Hwang, Jimmy ^f   Schmotzer, Amy ^d   Ramanathan, Ramesh K ^d  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e Edward Hospital   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced; Capecitabine; Docetaxel; Gastric adenocarcinoma; Gastroesophageal adenocarcinoma

Indexed keywords

CAPECITABINE; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; MULTICENTER STUDY; NEUROPATHY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTPATIENTS; PATIENT SELECTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; YOUNG ADULT;

EID: 77950625628     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000312654     Document Type: Article

References (20)

1. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 20 06; 24: 4991-4997.
2. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
3. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P: Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23: 494-501.
4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
5. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T: A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003; 64: 232-236. (Pubitemid 36438808)
6. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY: A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004; 15: 1344-1347.
7. Sakamoto J, Chin K, Kondo K, Kojima H, Terashima M, Yamamura Y, Tsujinaka T, Hyodo I, Koizumi W: Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 2006; 17: 231-236.
8. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB 3rd: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13: 87-93.
9. Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, Daglish B, Boudraa Y, Kim WS, Heo DS, Kim NK: Docetaxel 75 mg/m (2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002; 32: 248-254.
10. Sulkes A, Smyth J, Sessa C, Dirix LY, Ver-morken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994; 70: 380-383.
11. Giuliani F, Gebbia V, De V it a F, Maiello E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G: Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G. O. I. M.). Anticancer Res 2003; 23: 4219-4222.
12. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-1019.
13. Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC: Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2005; 155: 354-360. (Pubitemid 40379259)
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. Orditura M, Martinelli E, Galizia G, Carlomagno C, Aurilio G, Vecchione L, Lieto E, De Placido S, Catalano G, Ciardiello F, De Vita F: Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Ann Oncol 2006; 17: 1529-1532.
16. Park YH, Ryoo BY, Choi SJ, Kim HT: A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004; 90: 1329-1333.
17. Kim JG, Sohn SK, Kim DH, Baek JH, Sung WJ, Park JY, Kim TB, Jung HY, Yu W, Lee KB: Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68: 190-195.
18. Chun JH, Kim HK, Lee JS, Choi JY, Hwangbo B, Lee HG, Park SR, Choi IJ, Kim CG, Ryu KW, Kim YW, Lee JS, Bae JM: Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005; 28: 188-194.
19. Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ, Nikcevich DA: Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 7: 652-656.
20. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F: Capecitabine plus docetaxel every 3 weeks in first-and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 2005; 92: 2129-2133.